A Phase 1b Open-Label, Dose-Escalating Study to Evaluate the Safety and Tolerability of PLG0206 in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Occurring After Total Knee Arthroplasty (TKA)
Latest Information Update: 28 May 2025
At a glance
- Drugs PLG 0206 (Primary)
- Indications Bone and joint infections
- Focus Adverse reactions; Proof of concept
- Acronyms LOGIC-1
- Sponsors Peptilogics
Most Recent Events
- 21 May 2025 Status changed from active, no longer recruiting to completed.
- 19 Sep 2023 According to a Peptilogics media release, detailed analyses will be presented at various conferences in the coming months.
- 19 Sep 2023 Top line interim results published in a Peptilogics Media Release